WO2006137122A1 - 抗エイズ剤 - Google Patents
抗エイズ剤 Download PDFInfo
- Publication number
- WO2006137122A1 WO2006137122A1 PCT/JP2005/011297 JP2005011297W WO2006137122A1 WO 2006137122 A1 WO2006137122 A1 WO 2006137122A1 JP 2005011297 W JP2005011297 W JP 2005011297W WO 2006137122 A1 WO2006137122 A1 WO 2006137122A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- aids
- vllosum
- stevia
- present
- miq
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract description 9
- 229940079593 drug Drugs 0.000 title abstract description 7
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 claims abstract description 13
- 239000004480 active ingredient Substances 0.000 claims abstract description 4
- 208000030507 AIDS Diseases 0.000 claims description 41
- 241000266322 Melastoma Species 0.000 claims description 13
- 244000269722 Thea sinensis Species 0.000 claims description 13
- 241000245000 Kinugasa Species 0.000 claims description 11
- 240000001462 Pleurotus ostreatus Species 0.000 claims description 9
- 241000544066 Stevia Species 0.000 claims 5
- 244000228451 Stevia rebaudiana Species 0.000 abstract description 10
- 241000668730 Dipterocarpus obtusifolius Species 0.000 abstract description 6
- 235000013305 food Nutrition 0.000 abstract description 6
- 241001313710 Dictyophora indusiata Species 0.000 abstract description 2
- 229940124321 AIDS medicine Drugs 0.000 abstract 1
- 235000019224 Camellia sinensis var Qingmao Nutrition 0.000 abstract 1
- 241000218554 Lyophyllum Species 0.000 abstract 1
- 240000005338 Melastoma malabathricum Species 0.000 abstract 1
- 235000014435 Mentha Nutrition 0.000 abstract 1
- 241001072983 Mentha Species 0.000 abstract 1
- 235000020339 pu-erh tea Nutrition 0.000 abstract 1
- 239000000047 product Substances 0.000 description 27
- 239000003795 chemical substances by application Substances 0.000 description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 238000000605 extraction Methods 0.000 description 11
- 241000725303 Human immunodeficiency virus Species 0.000 description 10
- 239000000284 extract Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 8
- 239000000843 powder Substances 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 235000013616 tea Nutrition 0.000 description 6
- 238000003809 water extraction Methods 0.000 description 6
- 241000411851 herbal medicine Species 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 241000700605 Viruses Species 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 235000012149 noodles Nutrition 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 240000002900 Arthrospira platensis Species 0.000 description 1
- 235000016425 Arthrospira platensis Nutrition 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 241000195649 Chlorella <Chlorellales> Species 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 241000907904 Dipterocarpus Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 241000218556 Lyophyllum shimeji Species 0.000 description 1
- 244000103635 Lyophyllum ulmarium Species 0.000 description 1
- 235000015934 Lyophyllum ulmarium Nutrition 0.000 description 1
- 240000007707 Mentha arvensis Species 0.000 description 1
- 235000018978 Mentha arvensis Nutrition 0.000 description 1
- 235000016278 Mentha canadensis Nutrition 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- 241000219492 Quercus Species 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000006092 Stevia rebaudiana Nutrition 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- -1 pH adjusters Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 235000012015 potatoes Nutrition 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 229940082787 spirulina Drugs 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to an anti-AIDS agent.
- it relates to anti-AIDS agents that contain melastoma vllosum Loddj, Dipterocarpus obtusifolius I'eijsm ex Miq., Noodles, Kinugasa, Putuo tea, light load, and stevia.
- the present invention relates to anti-AIDS agents that contain melastoma vllosum Loddj, Dipterocarpus obtusifolius I'eijsm ex Miq., Noodles, Kinugasa, Putuo tea, light load, and stevia.
- AIDS is a severe immunodeficiency syndrome caused by infection with the virus responsible for it, human immunodeficiency virus (HIV).
- HAV human immunodeficiency virus
- crude drugs and herbal medicines have been used for the treatment and prevention of diseases.
- Many of these herbal medicines and herbal medicines have been confirmed to be safe and can be taken with peace of mind. Some of them have an antiviral effect that inhibits the growth of viruses and are attracting attention.
- herbal medicines used for prevention of AIDS virus infection, prevention and treatment of AIDS have been several reports on herbal medicines used for prevention of AIDS virus infection, prevention and treatment of AIDS.
- Stevia plants mainly stem and leaf extracts, suppresses the attachment, invasion, and fusion of HIV virus to lymphocytes, especially the binding of CD4 molecules of lymphocytes to HIV gpl 20 molecules. It is known to inhibit (see, for example, JP-A-11-335292). Also known is an anti-HIV active substance obtained by extracting a thin load with water and purifying the resulting extract by DEAE anion exchange chromatography (see, for example, JP-A-11-0 05745). . Also known are catechin or tannin AIDS therapeutic agents (see, for example, JP-A-2004-210762).
- the component derived from Kinugasatake is absorbed from the mucous membrane in the body and stimulates and activates mucosal immunity, and as a result, antitumor effects and treatment and improvement effects of viruses and bacteria such as AIDS are expected.
- the hot water extract of bunashimeji is dissolved in a lower alcohol aqueous solution, and the insoluble material is collected, and then it is extracted from karapaste, chlorella, spirulina, yeast extract, powder royal extract and powder propolis. It is known that immunostimulation occurs when the activity of helper T cells is extremely reduced in AIDS patients, etc.
- the present invention uses a natural product-derived herbal medicine that has been used in the past as a material, and is used regularly for a long time without serious side effects such as those seen in drugs. Is intended to provide a highly safe anti-AIDS agent.
- the purpose is selected from the group consisting of Melastoma vllosum Lodd., Diptero carpus obtusifolius Teijsm ex Miq., Shimeji, Kinugasa, Putuo tea, light load and stevia. This is achieved with anti-AIDS agents that contain one or more active ingredients.
- the anti-AIDS agent of the present invention exhibits remarkable anti-AIDS activity by continuous use. Moreover, because it is made from crude drugs and food materials that have been used safely for a long time, it can be prepared at low cost because it is easy to obtain highly safe ingredients without the serious side effects seen in chemicals. . In addition, the anti-AIDS agent of the present invention can reduce AIDS virus in daily life.
- Melastoma vllosum Lodd. which is the raw material of the present invention, uses a leaf part, and Dipteroca ⁇ us obtusifolius Teijsm ex Miq. Uses a real part.
- these dried products have long been widely used as crude drugs in Southeast Asia including Thailand, so there are no safety issues.
- the shimeji, scientific name (Lyophyl lum shimeji), which is a raw material of the present invention, is a genus of the genus Syzyme family that grows in miscellaneous forests such as Quercus and Kunugi, and since it has been eaten since ancient times, there is no problem in safety.
- Kinugasa candy the scientific name (Dictyophora indusiata), which is the raw material of the present invention, is a cradle of the cradle family that grows or spreads on the ground, such as bamboo forests and broad-leaved forests, and has been used for Chinese food since ancient times. There is no problem with sex. Putuocha, the raw material of the present invention, is a fermented green tea that has been fermented with Koji fungus for more than 3 years. It is also called black tea in China and has been drunk for over 1700 years. No problem.
- the light-weight and scientific name (Mentha arvensis) used as the raw material of the present invention is a perennial plant classified as the genus Lamiaceae, and since it has a high content of menthol, it has long been used for fragrances and medicinal purposes. There is no problem with sex.
- Stevia as a raw material of the present invention is Stevia rebaudiana Bert oni, a perennial plant of the family Asteraceae native to South America, and has no problem in safety because it is widely used as a sweetener.
- the anti-AIDS agent of the present invention is melastoma vllosum Lodd., Dipterocarpus obtusifohus Teijsm ex Miq., Shimesh, Kinugaa ear, common ear tea, '?
- hot water extraction may be performed in a raw state, but hot water extraction is preferably performed in a dry state.
- the dried product is further roasted and then extracted with hot water.
- the hot water extract can be spray-dried or freeze-dried and used as extract powder, granules, tablets, etc.
- the anti-AIDS agent of the present invention is effective even if it is taken as it is as a dry pulverized product or roasted pulverized product without hot water extraction.
- the dried product or roasted product may be extracted with hot water as it is, or from a practical aspect, it may be extracted from a product that has been further pulverized.
- the weight ratio between the hot water used as the extraction solvent and the dried or roasted product is not particularly limited, but 10 to 50 times the amount of hot water, particularly the extraction operation, relative to the dried product or roasted product. In terms of efficiency, hot water of 20 to 40 times weight is preferred.
- the extraction temperature is efficient at a high temperature, but the extraction can be performed sufficiently even at a low temperature. Especially good at 70-100 ° C.
- the extraction time may be determined appropriately depending on the extraction temperature and extraction time, which can be long or short, as long as the active ingredient can be extracted. .
- the extraction may be performed under pressure, normal pressure, or reduced pressure. Particularly preferred extraction conditions are normal pressure, extraction temperature 85 to 100 ° C, and extraction time 30 to 60 minutes.
- the roasting method is as follows: Melastoma vllosum Lodd., Futano Kakiki (Dipterocarpus obtusifolius Teijsm ex Miq.), Cymen, Kinugasa; ⁇ , Common ear tea, Light load and Stevia.
- Melastoma vllosum Lodd. Futano Kakiki (Dipterocarpus obtusifolius Teijsm ex Miq.), Cymen, Kinugasa; ⁇ , Common ear tea, Light load and Stevia.
- roasting method any method may be used as long as it is a general method, that is, sand roasting, net roasting, hot air roasting, microwave roasting and the like.
- the roasting conditions such as roasting time and roasting temperature can be determined appropriately according to the amount to be roasted at one time. For example, when roasting 100g of mixture, roasting temperature 110 ⁇ : 130 ° C Range, roasting time 10 ⁇ : It is preferable to be in the range of 18 minutes,
- the dosage form of the anti-AIDS agent of the present invention is not particularly limited, and can be administered orally or parenterally.
- rectal administration, intranasal administration, vaginal administration, sublingual administration, intravaginal administration, intramuscular administration, subcutaneous administration, and intravenous administration can be performed.
- the anti-AIDS agent of the present invention is preferably administered orally.
- the dosage form of the anti-AIDS agent of the present invention is not particularly limited, and can be appropriately selected according to the administration route and the like.
- tablets, capsules, powders, fine granules, granules, solutions, syrups and the like can be mentioned as preparations suitable for oral administration.
- Injections, infusions and drops are suitable as preparations suitable for parenteral administration. Suppositories, inhalants, transdermal absorbents, transmucosal absorbents, patches and the like.
- the injection may be used for any of intravenous injection, intramuscular injection, subcutaneous injection, infusion, etc., but is preferably an oral preparation.
- a pharmacologically and pharmaceutically acceptable additive can be added to the anti-AIDS agent of the present invention as necessary.
- the anti-AIDS agent of the present invention can have various functions.
- the anti-AIDS active substance can be designed so as to be released as required. It can also be designed so that the anti-AIDS active substance is intensively released at the required location in the body.
- sustained release drug delivery systems can be designed and manufactured according to methods well known in the pharmaceutical industry.
- an organic or inorganic carrier can be used for the anti-AIDS agent of the present invention.
- examples of such carriers include lactose, starch, vegetable and animal fats and oils.
- the dose of the anti-AIDS agent of the present invention depends on various conditions such as the purpose of treatment or prevention, the sex, weight, age, type and degree of disease, dosage form, administration route, number of administrations, etc. of the patient.
- the hot water extract is spray-dried or freeze-dried and used as extract powder, granules, tablets, etc., 4.0 to 7. Og is appropriate.
- the anti-AIDS agent of the present invention includes, for example, soups, various beverages (juice, liquor, mineral water, coffee, tea, etc.), confectionery (gum, candy, chocolate, snack, jelly, etc.). It can be added to general foods such as potatoes (buckwheat noodles, noodles, ramen, etc.), health foods, and nutritional supplements (nutrient drinks, etc.). This makes it possible to take an anti-AIDS agent without resistance in daily life.
- the concentration of the anti-AIDS agent in the food and drink of the present invention can be appropriately changed depending on the type of the food and drink.
- the extract powder obtained by spray drying or freeze-drying the hot water extract is used.
- the daily intake is preferably 2.0 to 12. Og, more preferably 4.0 to 7. Og.
- the above concentration is an example. These can be appropriately changed according to various situations.
- a clinical test for measuring the anti-AIDS effect of the product of the present invention was performed as follows.
- the anti-AIDS agent of the present invention was extracted twice a day with hot water at 90-100 ° C for 40 minutes and taken. Blood is collected regularly during the period of taking the HIV antigen.
- RNA concentration of RNA was measured. The results are shown in Fig. 1.
- FIG. 1 is a graph showing the average concentration of blood HIV antigen RNA in 24 AIDS patients who are still taking the anti-AIDS agent of the present invention.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2005/011297 WO2006137122A1 (ja) | 2005-06-20 | 2005-06-20 | 抗エイズ剤 |
JP2007522146A JPWO2006137122A1 (ja) | 2005-06-20 | 2005-06-20 | 抗エイズ剤 |
US11/993,082 US7638146B2 (en) | 2005-06-20 | 2005-06-20 | Anti-AIDS drug |
CA002612945A CA2612945A1 (en) | 2005-06-20 | 2005-06-20 | Anti-aids agent |
EP05751388A EP1917967A4 (en) | 2005-06-20 | 2005-06-20 | DRUG AGAINST AIDS |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2005/011297 WO2006137122A1 (ja) | 2005-06-20 | 2005-06-20 | 抗エイズ剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006137122A1 true WO2006137122A1 (ja) | 2006-12-28 |
Family
ID=37570175
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/011297 WO2006137122A1 (ja) | 2005-06-20 | 2005-06-20 | 抗エイズ剤 |
Country Status (5)
Country | Link |
---|---|
US (1) | US7638146B2 (ja) |
EP (1) | EP1917967A4 (ja) |
JP (1) | JPWO2006137122A1 (ja) |
CA (1) | CA2612945A1 (ja) |
WO (1) | WO2006137122A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010018546A (ja) * | 2008-07-10 | 2010-01-28 | Nippon Zettoc Co Ltd | コラゲナーゼ阻害剤、皮膚外用剤、口腔用組成物及び食品 |
WO2019189292A1 (ja) * | 2018-03-27 | 2019-10-03 | 株式会社雪国まいたけ | ウイルス感染症の治療剤及び/又は予防剤 |
JP2021523722A (ja) * | 2018-05-14 | 2021-09-09 | ソウル大学校産学協力団Seoul National University R&Db Foundation | Pmyong2ベクターシステムを用いたhiv−1 p24を発現する組換えbcg及びそのhiv−1ワクチンへの利用 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101618050B (zh) * | 2009-07-23 | 2011-06-15 | 无限极(中国)有限公司 | 一种具有增强免疫力功能的复合真菌多糖及其应用 |
WO2012026748A2 (ko) * | 2010-08-24 | 2012-03-01 | 한국한의학연구원 | 모임 추출물 또는 이의 분획물을 유효성분으로 함유하는 당뇨합병증 예방 및 치료용 약학적 조성물 |
KR101325215B1 (ko) | 2010-08-24 | 2013-11-04 | 한국 한의학 연구원 | 모임 추출물 또는 이의 분획물을 유효성분으로 함유하는 당뇨합병증 예방 및 치료용 약학적 조성물 |
KR101951782B1 (ko) * | 2010-10-25 | 2019-02-25 | (주)아모레퍼시픽 | 녹차 추출물을 함유하는 미백용 화장료 조성물 |
KR101440489B1 (ko) * | 2011-06-29 | 2014-09-17 | 한국생명공학연구원 | 디프테로카퍼스 옵터시포리어스 추출물을 유효성분으로 함유하는 염증성 질환 또는 알레르기 질환의 예방 및 치료용 약학적 조성물 |
CN106472510A (zh) * | 2016-10-10 | 2017-03-08 | 贵州省生物研究所 | 竹荪菌盖活性粉、制备方法及活性粉的应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11335292A (ja) * | 1998-03-26 | 1999-12-07 | Naohiko Sato | ステビア由来抗hiv活性物質 |
WO2002087603A1 (fr) | 2001-04-27 | 2002-11-07 | Ajinomoto Co., Inc. | Immunostimulants |
JP2004059558A (ja) * | 2002-07-29 | 2004-02-26 | Seimei Kagaku Kenkyusho:Kk | きのこ類から生理活性物質の採取法及びその生理活性物質の製剤及びその使用法 |
JP2004210762A (ja) * | 2003-01-08 | 2004-07-29 | Masami Uchiyama | エイズのためのカテキン錠他 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5558080A (en) * | 1978-10-20 | 1980-04-30 | Tsuneo Suzuki | Preparation of sugarless sweetener for infusion |
DE3801900A1 (de) * | 1988-01-23 | 1989-09-07 | Nink Karl Heinz | Verwendung von terpen-haltigen aetherischen oelen zur bekaempfung von aids und arc, sowie sie enthaltende pharmazeutische zubereitungen |
JP3072321B2 (ja) | 1997-06-13 | 2000-07-31 | 工業技術院長 | 抗hiv活性物質およびその製造方法 |
-
2005
- 2005-06-20 CA CA002612945A patent/CA2612945A1/en not_active Abandoned
- 2005-06-20 WO PCT/JP2005/011297 patent/WO2006137122A1/ja active Application Filing
- 2005-06-20 US US11/993,082 patent/US7638146B2/en not_active Expired - Fee Related
- 2005-06-20 JP JP2007522146A patent/JPWO2006137122A1/ja not_active Ceased
- 2005-06-20 EP EP05751388A patent/EP1917967A4/en not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11335292A (ja) * | 1998-03-26 | 1999-12-07 | Naohiko Sato | ステビア由来抗hiv活性物質 |
WO2002087603A1 (fr) | 2001-04-27 | 2002-11-07 | Ajinomoto Co., Inc. | Immunostimulants |
JP2004059558A (ja) * | 2002-07-29 | 2004-02-26 | Seimei Kagaku Kenkyusho:Kk | きのこ類から生理活性物質の採取法及びその生理活性物質の製剤及びその使用法 |
JP2004210762A (ja) * | 2003-01-08 | 2004-07-29 | Masami Uchiyama | エイズのためのカテキン錠他 |
Non-Patent Citations (5)
Title |
---|
DATABASE CAPLUS [online] SIV.YEIM YOK ET AL: "Flavonoids from Cambodian plants belonging to genera Canaga, Colonga, Grewia,Leea, and Melastoma.", XP002991388, accession no. stn Database accession no. (1973:88506) * |
LIN, JEAN-KUN ET AL: "Survey of Catechins, Gallic Acid, and Methylxanthines in Green, Oolong, Pu-erh, and Black Teas.", J AGRIC FOOD CHEM., vol. 46, no. 9, 1998, pages 3635 - 3642, XP002991389 * |
PLANTES MEDICINALES ET PHYTOTHERAPIE., vol. 6, no. 4, 1972, pages 299 - 305 * |
See also references of EP1917967A4 |
XU HONG-XI ET AL: "Inhibitory activity of flavonoids and tannis against HIV-1 protease.", BIOL PHARM BULL., vol. 23, no. 9, 2000, pages 1072 - 1076, XP002991390 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010018546A (ja) * | 2008-07-10 | 2010-01-28 | Nippon Zettoc Co Ltd | コラゲナーゼ阻害剤、皮膚外用剤、口腔用組成物及び食品 |
WO2019189292A1 (ja) * | 2018-03-27 | 2019-10-03 | 株式会社雪国まいたけ | ウイルス感染症の治療剤及び/又は予防剤 |
JP2021523722A (ja) * | 2018-05-14 | 2021-09-09 | ソウル大学校産学協力団Seoul National University R&Db Foundation | Pmyong2ベクターシステムを用いたhiv−1 p24を発現する組換えbcg及びそのhiv−1ワクチンへの利用 |
Also Published As
Publication number | Publication date |
---|---|
US7638146B2 (en) | 2009-12-29 |
EP1917967A4 (en) | 2011-08-17 |
CA2612945A1 (en) | 2006-12-28 |
EP1917967A1 (en) | 2008-05-07 |
JPWO2006137122A1 (ja) | 2009-01-08 |
US20080199488A1 (en) | 2008-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006137122A1 (ja) | 抗エイズ剤 | |
TWI787950B (zh) | 用於預防、緩解或治療冠狀病毒感染的包括杜英萃取物作為活性成分之藥物組成物以及食品組成物 | |
KR101613693B1 (ko) | 괭생이 모자반 추출물을 유효성분으로 포함하는 아토피성 피부질환 예방 또는 치료용 조성물 및 이의 제조방법 | |
US20190076496A1 (en) | Polysaccharide digestion inhibitor | |
KR20140104652A (ko) | 딱지꽃 추출물을 유효성분으로 포함하는 항인플루엔자용 조성물 | |
WO2016190566A9 (ko) | 아위버섯 물 추출물을 유효성분으로 함유하는 대사성질환의 예방 및 치료용 약학적 조성물 또는 건강기능성식품 | |
KR101182824B1 (ko) | 초피 열매 추출물 또는 이로부터 분리된 당단백질을 함유하는 항알레르기성 조성물 | |
KR101675064B1 (ko) | 복합추출물을 함유하는 운동수행능력 증강 및 체력증진용 조성물 | |
KR101828562B1 (ko) | 귤나무속 열매 발효물을 유효성분으로 포함하는 항바이러스용 조성물 | |
KR101039110B1 (ko) | 닥나무 물 추출물을 함유하는 면역기능 강화용 조성물 | |
KR20210002378A (ko) | 송화분 추출물을 유효성분으로 포함하는 간 보호용 조성물 | |
KR101732483B1 (ko) | 연교 추출물을 유효성분으로 함유하는 말초신경병증 예방, 개선 또는 치료용 조성물 | |
KR101680013B1 (ko) | 자단향 추출물을 유효성분으로 함유하는 알레르기성 질환 예방 또는 치료용 약학적 조성물 | |
KR101770572B1 (ko) | 상지 또는 상백피 추출물을 유효성분으로 함유하는 선천면역 증진 및 항바이러스용 조성물 | |
KR20140106198A (ko) | 귤나무속 열매 발효물을 유효성분으로 포함하는 항바이러스용 조성물 | |
JP2004352626A (ja) | 植物由来成分を含有する抗コレステロール剤 | |
KR20130123947A (ko) | 단삼 추출물을 포함하는 면역 증강 및 항바이러스 조성물 | |
RU2780346C1 (ru) | Терапевтический агент против коронавируса, включающий экстракт elaeocarpus sylvestris | |
KR101904819B1 (ko) | 여주와 마늘을 바실러스 아밀로리퀴페시언스 Jis-1로 발효한 추출물을 유효성분으로 하는 혈당강하 또는 당뇨병 예방 또는 치료용 조성물 | |
CN106074824A (zh) | 增强免疫力和预防治疗流感的组合物、制备工艺及用途 | |
KR20230054297A (ko) | 산자나무 열매 추출물 또는 분획물을 포함하는 항바이러스용 약학적 조성물 | |
KR20220161908A (ko) | 면역증진 또는 항바이러스용 조성물 | |
KR101662459B1 (ko) | 자단향 추출물을 유효성분으로 함유하는 알레르기성 질환 예방 또는 치료용 약학적 조성물 | |
TR2022008429T2 (tr) | Etkin madde olarak elaeocarpus sylvestris ekstraktı içeren koronavirüs terapötik ajanı. | |
KR20230076953A (ko) | 월견초 추출물을 포함하는 항바이러스용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005751388 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007522146 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2612945 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11993082 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2005751388 Country of ref document: EP |